RE:RE:RE:RE:RE:The potential oncology collaboration..
PWIB123 wrote: I would've expected JNCE's stock to skyrocket on the news of their recent partnership. The stock continued to drop. Does that concern anyone for our next potential moves with THTX?
PWIB123 wrote: I believe Jounce Therapeutics (JNCE) was used as an example of a deal that would be celebrated. Does it worry anybody that there was no big stock price jump on the news of that deal? Quite the opposite, the stock is continuing to drop.
scarlet1967 wrote: I believe the trial designs can be modified to serve the purpose for instance multi-center clinical trials with diverse ethnicity so the data can be presented to various related/targeted regional authorities, for instance THTX could start collaborating with a Chinese partner running trials in China the results from those centers and other centers can be presented to Chinese and other relevant authorities outside China or they can of course let the Chinese run their own trials. Thats my undrestanding, possibly a bit more complex and then add the politics to the mix!!
Wino115 wrote: Should have listed on HKSE instead of NASDAQ. We'd have $3bil mkt cap by now. ;-)
I think a deal will come fairly quickly on the back of just announcing they will be filing at least one pivotal for a specific cancer. They can then get full value on that with a partner and the partner can get first look at anything else, knowing full well they'll have to pay "market" at that time on whatever that indication is. I am not totally familiar with Chineses "FDA-like" approval processes but I would think it's like most countries where trials are for specific uses only and based solely on trial data (perhaps globally but I don't know).
I fully agree with Wino about the importance of frequent/transparent messaging…. targeting biggest possible audience….
It looks like they had about $100M before the deal with Gilead(September 2020 collaboration agreement), got $120.0 million in proceeds from the license and stock purchase agreements with Gilead, they completed the sale for a previous ATM ($30M) in January 2021,had an offering March 2021 ($56M), had license and collaboration revenue ($25M) second quarter 2021.As of June 30, 2022, they had about $160M and the last payment($15m) was a milestone payment(collaboration).The company estimates an annual cash burn between $115M to $130M. As for their oncology pipeline (refractory tumors/different science and financial prospects) they have stopped the “select” a phase 2 trial (it didn’t meet the end pints) now down to two ongoing trials a phase 2 and a phase1/2 as per the link below, the drug (GS-1811) still in Phase 1 and run by GILED.
In September 2020 after the partnership announcement their valuation increased almost by %100 from August 2020 lows to September 2020 highs, in January 2021 it reached the multi years high and since then it gave up the gains now at multi year lows.
This company currently valued about $100M, seems to have a quite significant cash burn, they gave away very early the exclusive license agreement for their drug although they are entitled to $645M in future clinical, regulatory and commercial milestone payments if this trial goes all the way to approval/commercialization, but still early in the process, last but not least has no commercial revenues, no NASH asset and add Tesamorelin’s ongoing clinical trials targeting other conditions than lipodystrophy.
My take is it is quite a different company compared to THTX, they managed to strike a sweet deal with GILED fairly early for one of their drugs which is still at pahse1 stage, has burn quite a bit of cash over the years, their flagship trial has failed and has no commercial revenues. THTX didn’t want to start any collaboration for the oncology program early since the further the trial advances/ derricks the more added value to a potential collaboration and its future clinical/financial prospects.
Our Pipeline | Jounce Therapeutics